AstraZeneca, facing lung cancer challenge from J&J, touts life-extension benefit for Tagrisso combo

Following an FDA approval last year based on a tumor progression benefit, AstraZeneca said Monday that its Tagrisso combination with chemotherapy extended patients’ lives compared with Tagrisso alone in first-line EGFR-mutated NSCLC.